Trial reportBMC infectious diseases2026
Albuvirtide plus 3BNC117 provides a promising combination strategy for multidrug-resistant HIV-1 infection: a prospective, open-label, multicenter phase 2 trial.
Trial report in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04560569 (A Multicenter, Two-Arm, 24-Week Study of Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter, Two-Arm, 24-Week Study of Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundAlbuvirtide (ABT), a fusion inhibitor, and 3BNC117, a broadly neutralizing antibody, were evaluated for efficacy and safety in combination with an optimized background regimen (OBR) in adults with multidrug-resistant (MDR) HIV-1.
methodsIn this phase 2 trial conducted in China via an international collaborative screening effort, we enrolled MDR HIV-1 patients with prior treatment failures and baseline viral loads > 1000 copies/mL. After a 6-day control period on existing therapy, participants received 3BNC117 on day 7 and ABT on days 7-9. On day 14, eligible patients were randomized 1:1 to Group A (ABT once weekly and 3BNC117 once every two weeks) or Group B (ABT and 3BNC117 once every two weeks), each with an OBR containing at least one fully active drug, for 24 weeks. The primary endpoint was the proportion with ≥ 0.5 log
resultsSixteen patients completed the study. Baseline mean viral load was 4.47 log
conclusionsIn patients with MDR HIV-1 infection who have limited treatment therapeutic options, the combination of ABT+3BNC117 plus an OBR was observed to have significant antiviral activity during a 34-week study period.
trial registrationClinicaltrials.gov NCT04560569, Sep 23, 2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.